loading
Iterum Therapeutics Plc stock is traded at $1.285, with a volume of 524.89K. It is down -2.99% in the last 24 hours and up +27.41% over the past month. Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
See More
Previous Close:
$1.32
Open:
$1.27
24h Volume:
524.89K
Relative Volume:
0.23
Market Cap:
$29.03M
Revenue:
-
Net Income/Loss:
$-35.58M
P/E Ratio:
-0.2843
EPS:
-4.52
Net Cash Flow:
$-42.82M
1W Performance:
-11.69%
1M Performance:
+27.41%
6M Performance:
-17.39%
1Y Performance:
+70.73%
1-Day Range:
Value
$1.24
$1.32
1-Week Range:
Value
$1.16
$1.44
52-Week Range:
Value
$0.705
$2.50

Iterum Therapeutics Plc Stock (ITRM) Company Profile

Name
Name
Iterum Therapeutics Plc
Name
Phone
(872) 225-6077
Name
Address
FITZWILLIAM COURT, 1ST FLOOR, DUBLIN 2
Name
Employee
14
Name
Twitter
Name
Next Earnings Date
2024-08-14
Name
Latest SEC Filings
Name
ITRM's Discussions on Twitter

Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades

Date Action Analyst Rating Change
May-28-21 Upgrade Gabelli & Co Sell → Hold
Mar-15-21 Upgrade H.C. Wainwright Neutral → Buy
Jun-02-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jan-21-20 Downgrade Gabelli & Co Buy → Sell
Dec-11-19 Downgrade SVB Leerink Outperform → Mkt Perform
Jun-21-19 Initiated H.C. Wainwright Buy
View All

Iterum Therapeutics Plc Stock (ITRM) Latest News

pulisher
Nov 01, 2024

Iterum Therapeutics defers $20 million FDA milestone payment By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Iterum Therapeutics defers $20 million FDA milestone payment - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

Iterum Therapeutics : Financial Obligation Form 8 K - Marketscreener.com

Nov 01, 2024
pulisher
Oct 29, 2024

ITRMIterum Therapeutics plc Ordinary Share Latest Stock News & Market Updates - StockTitan

Oct 29, 2024
pulisher
Oct 29, 2024

FDA Approves Oral Sulopenem (Orlynvah) for Uncomplicated Urinary Tract Infections - Contagionlive.com

Oct 29, 2024
pulisher
Oct 28, 2024

Iterum Scores First Approval For Oral Penem Antibiotic - Citeline

Oct 28, 2024
pulisher
Oct 28, 2024

Second Oral UTI Treatment Approved, But Still No Vaccine - Precision Vaccinations

Oct 28, 2024
pulisher
Oct 28, 2024

Biotech Alert: Searches spiking for these stocks today - TipRanks

Oct 28, 2024
pulisher
Oct 28, 2024

FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships - Benzinga

Oct 28, 2024
pulisher
Oct 28, 2024

FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment - Pharmaceutical Technology

Oct 28, 2024
pulisher
Oct 28, 2024

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - BioSpace

Oct 28, 2024
pulisher
Oct 28, 2024

NaoTrac to Redefine Surgical Navigation Robotics at MEDICA 2024 - Lelezard

Oct 28, 2024
pulisher
Oct 26, 2024

Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs - MSN

Oct 26, 2024
pulisher
Oct 26, 2024

Major Improvements In Iterum Therapeutics Plc (ITRM) Stock Need To Be Considered - Stocks Register

Oct 26, 2024
pulisher
Oct 26, 2024

FDA approves new oral antibiotic ORLYNVAH for uUTIs By Investing.com - Investing.com Nigeria

Oct 26, 2024
pulisher
Oct 25, 2024

Iterum Therapeutics (ITRM) Scores FDA Approval for New UTI Drug ORLYNVAH™ - BP Journal

Oct 25, 2024
pulisher
Oct 25, 2024

Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com

Oct 25, 2024
pulisher
Oct 25, 2024

Wall Street-Heavily Traded - WDRB

Oct 25, 2024
pulisher
Oct 25, 2024

Iterum Therapeutics Shares Soar on FDA's Orlynvah Approval - Marketscreener.com

Oct 25, 2024
pulisher
Oct 25, 2024

FDA approves new oral antibiotic ORLYNVAH for uUTIs - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

Iterum Therapeutics Gains FDA Approval for ORLYNVAH - TipRanks

Oct 25, 2024
pulisher
Oct 25, 2024

US FDA approves Iterum's treatment for urinary infection - Reuters.com

Oct 25, 2024
pulisher
Oct 25, 2024

Iterum Therapeutics announces FDA approval of Orlynvah - TipRanks

Oct 25, 2024
pulisher
Oct 25, 2024

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - The Manila Times

Oct 25, 2024
pulisher
Oct 20, 2024

Week Ahead (Jul.26-30): INFI To Provide Update On Eganelisib Trials, Writing's On The Wall For ITRM? - RTTNews

Oct 20, 2024
pulisher
Oct 15, 2024

Renaissance Technologies LLC Trims Stock Holdings in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World

Oct 15, 2024
pulisher
Oct 10, 2024

Iterum Therapeutics to Present Data at IDWeek 2024 - StockTitan

Oct 10, 2024
pulisher
Oct 09, 2024

Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit - The Manila Times

Oct 09, 2024
pulisher
Oct 08, 2024

Iterum Therapeutics shareholders approve share issuance authority - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Iterum Therapeutics shareholders approve share issuance authority By Investing.com - Investing.com Canada

Oct 08, 2024
pulisher
Oct 04, 2024

Iterum Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

Iterum Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com UK

Oct 04, 2024
pulisher
Sep 30, 2024

Biotech Stocks Facing FDA Decision In October 2024 - RTTNews

Sep 30, 2024
pulisher
Sep 18, 2024

IDWeek 2022 PresentationsIVVD, SPRO, INVA, CDTX, ANTX, GSK - RTTNews

Sep 18, 2024
pulisher
Sep 11, 2024

Nothing is Better Than Iterum Therapeutics Plc (ITRM) stock at the moment - SETE News

Sep 11, 2024
pulisher
Sep 11, 2024

ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down - Yahoo Finance

Sep 11, 2024
pulisher
Sep 11, 2024

Iterum Therapeutics’ (ITRM) Buy Rating Reaffirmed at HC Wainwright - Defense World

Sep 11, 2024
pulisher
Sep 10, 2024

Iterum's oral antibiotic discussed at FDA advisory meeting - Investing.com India

Sep 10, 2024
pulisher
Sep 10, 2024

Iterum stock falls 9% in wake of FDA AdComm meeting on UTI drug - MSN

Sep 10, 2024
pulisher
Sep 10, 2024

A closer look at ITRM’s price-to-free cash flow ratio - US Post News

Sep 10, 2024
pulisher
Sep 10, 2024

Iterum stock falls 9% in wake of FDA AdComm meeting on UTI drug (NASDAQ:ITRM) - Seeking Alpha

Sep 10, 2024
pulisher
Sep 10, 2024

Iterum's oral antibiotic discussed at FDA advisory meeting By Investing.com - Investing.com Canada

Sep 10, 2024
pulisher
Sep 10, 2024

Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment - EIN News

Sep 10, 2024
pulisher
Sep 09, 2024

Iterum Therapeutics Plc (ITRM)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Sep 09, 2024
pulisher
Sep 09, 2024

FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI - Urology Times

Sep 09, 2024
pulisher
Sep 06, 2024

Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference - StockTitan

Sep 06, 2024
pulisher
Sep 06, 2024

Iterum Therapeutics Plc (ITRM)’s highs and lows: A closer look at its stock price fluctuations - US Post News

Sep 06, 2024
pulisher
Sep 05, 2024

Adcom next stop for Iterum amid AMR concerns - BioWorld Online

Sep 05, 2024

Iterum Therapeutics Plc Stock (ITRM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):